Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Because ankle brachial index and pulse wave velocity data were available for further analysis, we have not presented the vascular calcification scores here.Patient characteristics and comparison between patients with above: and below-median sclerostin levelsCharacteristicsTotalSclerostin≥ 80.2 pmol/LSclerostin< 80.2 pmol/LP valueNumber of patients894544Age (year)49.2 ± 10.651.4 ± 10.347.0 ± 10.60.048Sex-male44 (49.4)28 (62.2)16 (36.4)0.015Dialysis vintage (day)1490 (649 to 2392)1401 (742 to 2385)1777 (552 to 2431)0.752Weight (kg)62.5 ± 13.065.7 ± 12.359.2 ± 13.00.016Height (cm)162.4 ± 8.1164.1 ± 7.4160.7 ± 8.60.048BMI (kg/m2)23.6 ± 3.824.3 ± 3.722.8 ± 3.80.051Total Kt/V for urea1.95 (1.84 to 2.09)1.94 (1.82 to 2.08)1.97 (1.86 to 2.10)0.036Baseline comorbidities Diabetes mellitus13 (14.6)10 (22.2)3 (6.8)0.040 Hypertension62 (69.7)33 (73.3)29 (65.9)0.446 Parathyroidectomy17 (19.1)10 (22.2)7 (15.9)0.449 Anuria46 (51.7)24 (53.3)22 (50.0)0.753Serum biochemistry Sclerostin (pmol/L)80.2 (60.2 to 107)107.0 (87.0 to 135)69.1 (50.6 to 69.1)< 0.001 FGF-23 (pg/mL)3193 (1878 to 3547)3193 (2003 to 3442)3173(1863 to 3559)0.902 DKK-1 (pg/mL)981 ± 3561048 ± 402912 ± 2900.071 CTX (ng/mL)2.70 (2.14 to 3.38)2.68 (2.19 to 3.25)2.91 (2.08 to 3.66)0.408 25(OH)-Vitamin D (ng/mL)22.7 ± 7.524.2 ± 7.321.3 ± 7.40.067 Osteocalcin (ng/mL)177 (98.3 to 349)137 (97.3 to 264)228 (106 to 563)0.025 Intact PTH (pg/mL)315 (119 to 564)199 (111 to 458)399 (169 to 718)0.008 Urea nitrogen (mg/dL)64.7 ± 17.265.9 ± 16.463.5 ± 18.10.520 Creatinine (mg/dL)12.6 ± 2.913.3 ± 2.612.0 ± 3.00.038 Calcium (mg/dL)9.6 ± 0.79.5 ± 0.79.7 ± 0.70.345 Phosphorus (mg/dL)5.1 (4.3 to 6.0)5.1 (4.3 to 6.0)5.1 (4.2 to 6.2)0.735 Magnesium (mg/dL)2.1 ± 0.42.1 ± 0.42.1 ± 0.40.994 Albumin (g/dL)3.9 (3.7 to 4.1)3.9 (3.7 to 4.2)3.9 (3.7 to 4.1)0.999 Alkaline phosphatase (U/L)104 (70 to 143)92 (68 to 120)115 (71 to 159.5)0.191 Cholesterol (mg/dL)186.0 ± 44.6183.4 ± 41.4188.7 ± 48.00.581 Triglyceride (mg/dL)141 (104 to 254)155 (88 to 257)132 (104 to 224)0.620 Hemoglobin (g/dL)10.5 (9.6 to 11.4)10.8 (9.8 to 11.6)10.4 (9.4 to 10.9)0.062 Glucose (mg/dL)96 (91 to 113)101 (92 to 122)93 (89 to 99.5)0.012 Uric acid (mg/dL)6.8 ± 1.47.1 ± 1.46.4 ± 1.30.021 hsCRP (mg/L)2.36 (0.81 to 8.97)3.53 (0.89 to 8.97)2.14 (0.54 to 7.91)0.548BMD, spine L1 to L4 (g/cm2)1.16 ± 0.181.22 ± 0.171.10 ± 0.180.001BMD spine T-score0.12 ± 1.500.56 ± 1.40−0.33 ± 1.470.004BMD spine Z-score0.32 ± 1.320.74 ± 1.31− 0.12 ± 1.190.002Ankle brachial index1.10 ± 0.091.09 ± 0.101.11 ± 0.080.352Pulse wave velocity (m/s)15.0 ± 2.515.1 ± 2.714.9 ± 2.20.783BMI body mass index, FGF-23 fibroblast growth factor 23, DKK-1 dickkopf-1, CTX cross-linked C-telopeptide of type 1 collagen, PTH parathyroid hormone, hsCRP high-sensitivity C-reactive protein, BMD bone mineral density

Source: Patient characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study

Source: Article title.

Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD: MBD-related markers.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study

Cross-sectional study · BMC Nephrology · 2019

Original publication title

Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study

Te-Hui Kuo; Wei-Hung Lin; Jo-Yen Chao; An-Bang Wu; Chin-Chung Tseng; Yu-Tzu Chang; Hung-Hsiang Liou; Ming-Cheng Wang

© The Author(s). 2019

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD): mineral and bone disorder (MBD), which has various forms of presentation, from osteoporosis to vascular calcification. The positive association of sclerostin with bone mineral density (BMD) has been demonstrated in CKD and hemodialysis (HD) patients but not in peritoneal dialysis (PD) patients. This study assessed the association between sclerostin and BMD in PD patients.

Source: Background

Abstract: What methods does the paper describe?

Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD: MBD-related markers. BMD was also assessed simultaneously. We examined the relationship between sclerostin and each parameter through Spearman correlation analysis and by comparing group data between patients with above: and below-median sclerostin levels. Univariate and multiple logistic regression models were employed to define the most predictive of sclerostin levels in the above-median category.

Source: Methods

Abstract: Results

Bivariate analysis revealed that sclerostin was correlated with spine BMD (r = 0.271, P = 0.011), spine BMD T-score (r = 0.274, P = 0.010), spine BMD Z-score (r = 0.237, P = 0.027), and intact parathyroid hormone (PTH; r = − 0.357, P < 0.001) after adjustments for age and sex. High BMD, old age, male sex, increased weight and height, diabetes, and high osteocalcin and uric acid levels were observed in patients with high serum sclerostin levels and an inverse relation was noticed between PTH and sclerostin.

Univariate logistic regression analysis demonstrated that BMD is positively correlated with above-median sclerostin levels (odds ratio [OR] = 65.61, P = 0.002); the correlation was retained even after multivariate adjustment (OR = 121.5, P = 0.007).

Source: Results

Abstract: Conclusions

For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.

Source: Conclusions
Authors’ abstract

Background

Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD): mineral and bone disorder (MBD), which has various forms of presentation, from osteoporosis to vascular calcification. The positive association of sclerostin with bone mineral density (BMD) has been demonstrated in CKD and hemodialysis (HD) patients but not in peritoneal dialysis (PD) patients. This study assessed the association between sclerostin and BMD in PD patients.

Methods

Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD: MBD-related markers. BMD was also assessed simultaneously. We examined the relationship between sclerostin and each parameter through Spearman correlation analysis and by comparing group data between patients with above: and below-median sclerostin levels. Univariate and multiple logistic regression models were employed to define the most predictive of sclerostin levels in the above-median category.

Results

Bivariate analysis revealed that sclerostin was correlated with spine BMD (r = 0.271, P = 0.011), spine BMD T-score (r = 0.274, P = 0.010), spine BMD Z-score (r = 0.237, P = 0.027), and intact parathyroid hormone (PTH; r = − 0.357, P < 0.001) after adjustments for age and sex. High BMD, old age, male sex, increased weight and height, diabetes, and high osteocalcin and uric acid levels were observed in patients with high serum sclerostin levels and an inverse relation was noticed between PTH and sclerostin.

Univariate logistic regression analysis demonstrated that BMD is positively correlated with above-median sclerostin levels (odds ratio [OR] = 65.61, P = 0.002); the correlation was retained even after multivariate adjustment (OR = 121.5, P = 0.007).

Conclusions

For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.

Publication and source details

Original title: Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study

Te-Hui Kuo; Wei-Hung Lin; Jo-Yen Chao; An-Bang Wu; Chin-Chung Tseng; Yu-Tzu Chang; Hung-Hsiang Liou; Ming-Cheng Wang

BMC Nephrology · 2019

© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100004844National Cheng Kung University Hospital10406030, 10505030, 10704006Kuo Te-Hui

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:28:33.497724+00:00

DOI: 10.1186/s12882-019-1452-5 · PMC6637583